Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2024-03-29 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document text is extremely short (613 characters) and consists solely of a digital signature block with no substantive content, financial data, or report information. There is no indication of a report, announcement, or any specific filing type. Given the lack of content and the presence of a digital signature, this document most likely represents a certification or attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2024-03-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (560 characters) and consists solely of a digital signature block with no substantive content, financial data, or report information. There is no indication of a report, announcement, or any other filing type. Given the lack of content and the nature of the text, this is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2024-03-27 English
Intimation of Schedule of Analyst/Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Regulatory Filings
2024-03-27 English
Disclosure under Regulation 7(2) of SEBI (PIT) Regulations, 2015 as amended ("SEBI PIT Regulations") Continual Disclosure
Regulatory Filings
2024-03-22 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Expert Chemicals India Pvt Ltd
Regulatory Filings
2024-03-22 English
Outcome of Day-to-Day Affairs Committee held on 21st March, 2024 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Regulatory Filings
2024-03-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.